The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Continuous Bio-Manufacturing Skid Market Expected To Change Between 2026 And 2030?
The continuous bio-manufacturing skid market has seen rapid expansion in recent years. Its valuation is predicted to increase from $1.99 billion in 2025 to $2.26 billion in 2026, at a compound annual growth rate (CAGR) of 13.6%. This historical growth can be linked to several factors, including an increase in biologics production volumes, an early shift from batch to continuous processing, the growing adoption of modular manufacturing concepts, the expansion of vaccine and enzyme production facilities, and a rising demand for flexible manufacturing setups.
The continuous bio-manufacturing skid market size is projected to experience substantial expansion over the upcoming years. This market is set to reach $3.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. Key factors driving this growth during the forecast period include the expanding implementation of fully continuous biologics production, increased investments in sophisticated bioprocess automation, a heightened need for swift scale-up abilities, the broadening of cell and gene therapy manufacturing, and an intensified emphasis on economical biologics production. Significant trends anticipated in this period encompass the wider acceptance of continuous and integrated bioprocessing skids, an escalating demand for modular and ‘plug-and-play’ manufacturing solutions, more widespread utilization of real-time process monitoring and control, the growth of single-use continuous biomanufacturing platforms, and a strengthened focus on optimizing process efficiency and throughput.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28999&type=smp
What Underlying Factors Are Accelerating The Growth Of The Continuous Bio-Manufacturing Skid Market?
The continuous bio-manufacturing skid market is anticipated to expand due to the increasing demand for biopharmaceuticals. Biopharmaceuticals are medical products developed from biological sources, such as proteins, nucleic acids, or living cells, for the purpose of treating, preventing, or diagnosing diseases. This rising demand for biopharmaceuticals is primarily fueled by the growing prevalence of chronic and genetic diseases, which necessitate advanced biologic therapies for effective treatment and management. Continuous bio-manufacturing skids enhance biopharmaceutical production by enabling streamlined, automated, and scalable processes that improve efficiency, consistency, and speed in developing complex therapies. For instance, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, the U.S. had 40 FDA-approved biosimilar products, with 25 available on the market. In comparison, as of January 2022, there were 33 FDA-approved biosimilars, of which 21 were commercially available. Consequently, the increasing demand for biopharmaceuticals is driving the growth of the continuous bio-manufacturing skid market.
How Is The Continuous Bio-Manufacturing Skid Market Structured Across Different Segments?
The continuous bio-manufacturing skid market covered in this report is segmented –
1) By Product Type: Single-Use Skids, Multi-Use Skids, Modular Skids
2) By Process: Upstream, Downstream, Integrated
3) By Application: Biopharmaceutical Production, Vaccine Manufacturing, Enzyme Production, Cell And Gene Therapy, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Institutes, Other End-Users
Subsegments:
1) By Single-Use Skids: Perfusion Bioreactor Skid, Tangential Flow Filtration Skid, Chromatography Skid, Buffer Preparation Skid
2) By Multi-Use Skids: Fed-Batch Bioreactor Skid, Downstream Purification Skid, Ultrafiltration Skid, Viral Inactivation Skid
3) By Modular Skid: Plug And Play Bioreactor Skid, Integrated Downstream Skid, Automated Sampling Skid, Real-Time Monitoring Skid
Which Trends Are Shaping The Future Of The Continuous Bio-Manufacturing Skid Market?
Leading companies in the continuous bio-manufacturing skid market are concentrating on developing innovative solutions, such as next-generation biologics manufacturing platforms, to enhance efficiency, scalability, and product quality. These next-generation biologics manufacturing platforms are advanced systems that facilitate fully connected, continuous production of biologics with real-time monitoring, superior efficiency, and consistent product quality. For instance, in October 2024, Enzene Biosciences Ltd., an India-based contract development and manufacturing organization, launched EnzeneX 2.0 at CPHI Milan 2024, representing the next iteration of its fully connected continuous manufacturing (FCCM) technology for biologics. This patented platform enables seamless, uninterrupted processing from perfusion to the final drug substance. By leveraging high-titer clones and optimized cell media, it improves productivity, raises target protein concentrations, and minimizes batch-to-batch variability. The system also integrates process analytical technology (PAT) for real-time monitoring and control, ensuring consistent quality and operational efficiency, while offering up to a 50% reduction in production costs per gram. These platforms provide scalable, cost-effective biologics manufacturing that can adapt to diverse modalities and media formulations.
Which Major Players Dominate The Continuous Bio-Manufacturing Skid Market?
Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.
Read the full continuous bio-manufacturing skid market report here:
Which Region Is Projected To Dominate The Continuous Bio-Manufacturing Skid Market During The Forecast Period?
North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in the continuous bio-manufacturing skid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Continuous Bio-Manufacturing Skid Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28999&type=smp
Browse Through More Reports Similar to the Global Continuous Bio-Manufacturing Skid Market 2026, By The Business Research Company
Digital Biomanufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/digital-biomanufacturing-global-market-report
Biopharmaceuticals Contract Manufacturing Market Report 2026
Bioengineering Technology Market Report 2026
https://www.thebusinessresearchcompany.com/report/bioengineering-technology-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model